Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 34
1993 15
1994 26
1995 38
1996 54
1997 80
1998 90
1999 158
2000 175
2001 230
2002 246
2003 308
2004 288
2005 341
2006 346
2007 309
2008 316
2009 320
2010 347
2011 361
2012 424
2013 516
2014 497
2015 559
2016 554
2017 594
2018 590
2019 639
2020 734
2021 665
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

8,950 results
Results by year
Filters applied: . Clear all
Page 1
Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, Bennett CL. Lu ZK, et al. Expert Opin Drug Saf. 2015 Feb;14(2):295-303. doi: 10.1517/14740338.2015.989210. Epub 2014 Dec 10. Expert Opin Drug Saf. 2015. PMID: 25494485 Free PMC article. Review.
INTRODUCTION: Azithromycin and levofloxacin have been shown to be efficacious in treating infections. The adverse drug events associated with azithromycin and levofloxacin were considered rare. However, the US FDA released warnings regarding the possible risk of QT …
INTRODUCTION: Azithromycin and levofloxacin have been shown to be efficacious in treating infections. The adverse drug events associa …
Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Izadi M, Dadsetan B, Najafi Z, Jafari S, Mazaheri E, Dadras O, Heidari H, SeyedAlinaghi S, Voltarelli F. Izadi M, et al. Recent Pat Antiinfect Drug Discov. 2018;13(3):228-239. doi: 10.2174/1574891X13666181024154526. Recent Pat Antiinfect Drug Discov. 2018. PMID: 30360748 Clinical Trial.
Although standard regimen group (n=27, 36%) showed more consolidation than patients in Levofloxacin group (n=22, 29.3%), and the ground glass pattern was observed more in Levofloxacin group. CONCLUSION: We concluded that monotherapy with oral Levofloxacin was …
Although standard regimen group (n=27, 36%) showed more consolidation than patients in Levofloxacin group (n=22, 29.3%), and the grou …
Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
Karampela I, Dalamaga M. Karampela I, et al. Arch Med Res. 2020 Oct;51(7):741-742. doi: 10.1016/j.arcmed.2020.06.004. Epub 2020 Jun 6. Arch Med Res. 2020. PMID: 32546446 Free PMC article.
Remarkably, fluoroquinolones have shown multiple immunomodulatory actions leading to an attenuation of the inflammatory response through the inhibition of pro-inflammatory cytokines. Noteworthy, respiratory fluoroquinolones, levofloxacin and moxifloxacin, constitute fist l …
Remarkably, fluoroquinolones have shown multiple immunomodulatory actions leading to an attenuation of the inflammatory response through the …
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T. Deshpande D, et al. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611. Clin Infect Dis. 2018. PMID: 30496461 Free PMC article.
BACKGROUND: Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown. ...CONCLUSIONS: The levofloxacin dose of 25 mg/kg or 1500 mg/day was adequate for replacement of high-dose moxifloxacin in treatment of multi …
BACKGROUND: Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown. ...CONCL …
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. Bennett AC, et al. Expert Opin Drug Saf. 2019 Nov;18(11):1055-1063. doi: 10.1080/14740338.2019.1665022. Epub 2019 Sep 18. Expert Opin Drug Saf. 2019. PMID: 31500468 Review.
Introduction: Ciprofloxacin, levofloxacin, and moxifloxacin belong to the fluoroquinolone class of antibiotics and are amongst the most commonly prescribed antibiotics. ...
Introduction: Ciprofloxacin, levofloxacin, and moxifloxacin belong to the fluoroquinolone class of antibiotics and are amongst the mo …
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC. Pranger AD, et al. Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Drugs. 2019. PMID: 30617959 Free PMC article. Review.
Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or i …
Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase t …
Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Grillon A, Schramm F, Kleinberg M, Jehl F. Grillon A, et al. PLoS One. 2016 Jun 3;11(6):e0156690. doi: 10.1371/journal.pone.0156690. eCollection 2016. PLoS One. 2016. PMID: 27257956 Free PMC article.
If MIC of ciprofloxacin and levofloxacin against the considered bacteria are far from clinical breakpoint, these two antibiotics are equivalent. According to our MIC50 and modal MIC, the breakpoints of both ciprofloxacin and levofloxacin seem to be somewhat high and …
If MIC of ciprofloxacin and levofloxacin against the considered bacteria are far from clinical breakpoint, these two antibiotics are …
Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis.
Bientinesi R, Murri R, Sacco E. Bientinesi R, et al. Expert Opin Pharmacother. 2020 Apr;21(6):637-644. doi: 10.1080/14656566.2020.1720647. Epub 2020 Jan 31. Expert Opin Pharmacother. 2020. PMID: 32004097
Treating complicated UTIs is extremely important due to their potential mortality. Levofloxacin is a fluoroquinolone antibacterial that has become one of the cornerstones of antibiotic therapy of complicated UTIs and pyelonephritis since its introduction in the 1990s becau …
Treating complicated UTIs is extremely important due to their potential mortality. Levofloxacin is a fluoroquinolone antibacterial th …
Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Yuan J, Mo B, Ma Z, Lv Y, Cheng SL, Yang Y, Tong Z, Wu R, Sun S, Cao Z, Wu J, Zhu D, Chang L, Zhang Y; Investigator Group of the Phase 3 Study on Oral Nemonoxacin. Yuan J, et al. J Microbiol Immunol Infect. 2019 Feb;52(1):35-44. doi: 10.1016/j.jmii.2017.07.011. Epub 2017 Aug 2. J Microbiol Immunol Infect. 2019. PMID: 30181096 Free article. Clinical Trial.
The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP. METHODS: A phase 3, multicenter, randomized (2:1) controlled trial was conducted in adult CAP patients receiving nemonoxacin 500 mg or levoflo
The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP. METHO …
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. Connolly LE, et al. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01989-17. doi: 10.1128/AAC.01989-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29378708 Free PMC article. Clinical Trial.
Patients were randomized 1:1:1 to receive intravenous plazomicin (10 or 15 mg/kg of body weight) or intravenous levofloxacin (750 mg) once daily for 5 days. Coprimary efficacy endpoints were microbiological eradication at the test of cure (TOC; 5 to 12 days after the last …
Patients were randomized 1:1:1 to receive intravenous plazomicin (10 or 15 mg/kg of body weight) or intravenous levofloxacin (750 mg) …
8,950 results